๐ข ๐๐๐๐ ๐๐: $Viking Therap(VKTX.US) Viking Therapeutics Launches Phase 1 Trial for New Weight-Loss Drug VK3019
๐ ๐๐๐ฒ ๐๐ข๐ ๐ก๐ฅ๐ข๐ ๐ก๐ญ๐ฌ:โค ๐๐ข๐ค๐ข๐ง๐ ๐๐ก๐๐ซ๐๐ฉ๐๐ฎ๐ญ๐ข๐๐ฌ initiated a ๐๐ก๐๐ฌ๐ ๐ trial of weight-loss candidate VK3019.โค VK3019 is a ๐๐ฎ๐๐ฅ ๐๐ฆ๐ฒ๐ฅ๐ข๐ง and ๐๐๐ฅ๐๐ข๐ญ๐จ๐ง๐ข๐ง receptor agonist (DACRA).โค Trial follows ๐ ๐๐ clearance of VK3019's Investigational New Drug application.โค Study will evaluate ๐ฌ๐๐๐๐ญ๐ฒ, ๐ญ๐จ๐ฅ๐๐ซ๐๐๐ข๐ฅ๐ข๐ญ๐ฒ, and pharmacokinetics in adults with BMI โฅ 30.โค Exploratory assessments include changes in ๐๐จ๐๐ฒ ๐ฐ๐๐ข๐ ๐ก๐ญ after a single dose.โค Preclinical data showed up to ๐% ๐๐จ๐๐ฒ-๐ฐ๐๐ข๐ ๐ก๐ญ reduction within 72 hours in animal studies.โค Viking is also conducting ๐๐ก๐๐ฌ๐ ๐ VANQUISH trials for obesity drug VK2735.โค Company plans to launch a ๐๐ก๐๐ฌ๐ ๐ trial of oral VK2735 later in 2026.๐ ๐๐ก๐ฒ ๐๐ญ ๐๐๐ญ๐ญ๐๐ซ๐ฌ:โค VK3019 expands Viking's pipeline in the rapidly growing ๐จ๐๐๐ฌ๐ข๐ญ๐ฒ treatment market.โค DACRA therapies could complement ๐๐๐-๐ and GLP-1/GIP weight-loss medicines.โค Success could provide additional ๐ฅ๐จ๐ง๐ -๐ญ๐๐ซ๐ฆ ๐ฐ๐๐ข๐ ๐ก๐ญ-๐ฆ๐๐ง๐๐ ๐๐ฆ๐๐ง๐ญ options for patients.๐ ๐๐ฑ๐ฉ๐๐ซ๐ญ ๐๐ญ๐๐ญ๐๐ฆ๐๐ง๐ญ:โค "The initiation of VK3019's Phase 1 study marks an important expansion of our portfolio of novel therapies designed to optimize the weight loss journey for patients and their physicians." โ ๐๐ซ๐ข๐๐ง ๐๐ข๐๐ง, Ph.D., Chief Executive Officer of Viking Therapeutics.โค "Therapies that target amylin and calcitonin receptors may potentially be used alone or in combination with GLP-1 or dual GLP-1/GIP agonists to improve the induction of weight loss as well as for longer-term weight management." โ ๐๐ซ๐ข๐๐ง ๐๐ข๐๐ง.โค "Broadening the potential treatment options is crucial to meeting the diverse needs of individuals seeking safe and sustainable weight loss." โ ๐๐ซ๐ข๐๐ง ๐๐ข๐๐ง.
Share your thoughtsWhat's on your mind?
0 / 2,000
- H
$Viking Therap(VKTX.US) | Truist Securities ๐ซ๐๐ข๐ญ๐๐ซ๐๐ญ๐๐ฌ ๐๐ฎ๐ฒ on ๐๐ข๐ค๐ข๐ง๐ ๐๐ก๐๐ซ๐๐ฉ๐๐ฎ๐ญ๐ข๐๐ฌ, ๐ซ๐๐ข๐ฌ๐๐ฌ ๐๐ ๐ญ๐จ $๐๐ ๐๐ซ๐จ๐ฆ $๐๐
Analyst sees VKTX as a differentiated obesity player, citing fast efficacy, flexible formulations for adherence, and a diversified metabolics pipeline. - H
๐ข ๐๐๐๐ ๐๐: $Viking Therap(VKTX.US) Viking Therapeutics Reports Phase 2 Oral VK2735 Obesity Data
๐ ๐๐๐ฒ ๐๐ข๐ ๐ก๐ฅ๐ข๐ ๐ก๐ญ๐ฌ:โค Oral ๐๐๐๐๐๐ achieved up to ๐๐.๐% weight loss in ๐๐ weeks.โค Placebo group recorded ๐.๐% average weight reduction.โค Trial enrolled ๐๐๐ adults with obesity or overweight conditions.โค Weight loss began by ๐ฐ๐๐๐ค ๐ and continued without plateauing.โค Up to ๐๐% of participants achieved at least ๐% weight loss.โค Treatment targets both ๐๐๐-๐ and ๐๐๐ receptors.โค Viking plans to launch ๐๐ก๐๐ฌ๐ ๐ trials for oral VK2735 this year. - M
Top earnings plays I am watching from today's reports
$Eli Lilly(LLY.US) $Viking Therap(VKTX.US) $Textron(TXT.US) $GE Vernova(GEV.US) $Teradyne(TER.US) $Intercontinental Exchange(ICE.US) - H
$Viking Therap(VKTX.US) | ๐๐ข๐ค๐ข๐ง๐ ๐๐ก๐๐ซ๐๐ฉ๐๐ฎ๐ญ๐ข๐๐ฌ: Raymond James reiterates ๐๐ญ๐ซ๐จ๐ง๐ ๐๐ฎ๐ฒ, maintains ๐๐ ๐๐ญ $๐๐๐
Analyst sees GLP-1/GIP data readthrough as neutral-to-positive, with no meaningful LBM disadvantage and stronger weight loss profile supporting VKTX outlook.Source: Hardik Shah
